nach oben

Medical Oncology

Erschienen in:

01.05.2015 | Original Paper

Endothelial cell protein C receptor promotes MGC803 gastric cancer cells proliferation and migration by activating ERK1/2

verfasst von: Qingling Wang, Qingru Liu, Tianyuan Wang, Hongli Yang, Zhengjie Han, Peng Zhang

Erschienen in: Medical Oncology | Ausgabe 5/2015

Einloggen, um Zugang zu erhalten

Abstract

The endothelial cell protein C receptor (EPCR) has been reported to be involved in the development of several human cancers. However, the role of EPCR in gastric cancer progression has not been clarified. In this study, we show for the first time that EPCR is related to gastric cancer. Our results indicate that EPCR is highly expressed in clinical gastric cancer tissue. Knockdown of EPCR by small interference RNA suppressed the proliferation and migration of MGC803 gastric cancer cells dominantly. Blocking antibodies to protease-activated receptor-1(PAR1) also suppressed the proliferation and migration of MGC803 cells. Knockdown EPCR and blocking PAR1 inhibit activation of extracellular signaling-regulated kinases 1 and 2 (ERK1/2). Taken together, these results indicate that EPCR contributes to the proliferation and migration of MGC803 gastric cancer cells by activating ERK1/2, and this effect of EPCR may be dependent on PAR1. Therefore, EPCR may be act as a novel therapeutic target for inhibiting cell growth in gastric cancer.

Globocan 2012. http://globocan.iarc.fr/. Accessed 31 March 2014.

Fock KM. Review article: the epidemiology and prevention of gastric cancer. Aliment Pharmacol Ther. 2014;40(3):250–60.CrossRefPubMed

McLean MH, El-Omar EM. Genetics of gastric cancer. Nat Rev Gastroenterol Hepatol. 2014;11(11):664–74.CrossRefPubMed

Zhaode Bu, Ji Jiafu. A current view of gastric cancer in China. Transl Gastrointest Cancer. 2013;2(S1):1–4.

Fukudome K, Esmon CT. Identification, cloning, and regulation of a novel endothelial cell protein C/activated protein C receptor. J Biol Chem. 1994;269(42):26486–91.PubMed

Haller H, Ziegler W, Lindschau C, et al. Endothelial cell tyrosine kinase receptor and G protein-coupled receptor activation involves distinct protein kinase C isoforms. Arterioscler Thromb Vasc Biol. 1996;16(5):678–86.CrossRefPubMed

Mosnier LO, Zlokovic BV, Griffin JH. The cytoprotective protein C pathway. Blood. 2007;109(8):3161–72.CrossRefPubMed

Mohan Rao LV, Esmon CT, Pendurthi UR. Endothelial cell protein C receptor: a multiliganded and multifunctional receptor. Blood. 2014;124(10):1553–62.CrossRefPubMed

Bouwens EA, Stavenuiter F, Mosnier LO. Mechanisms of anticoagulant and cytoprotective actions of the protein C pathway. J Thromb Haemost. 2013;11(Suppl 1):242–53.CrossRefPubMedCentralPubMed

10.

Sen P, Gopalakrishnan R, Kothari H, et al. Factor VIIa bound to endothelial cell protein C receptor activates protease activated receptor-1 and mediates cell signaling and barrier protection. Blood. 2011;117(11):3199–208.CrossRefPubMedCentralPubMed

11.

Thiyagarajan M, Cheng T, Zlokovic BV. Endothelial cell protein C receptor: role beyond endothelium? Circ Res. 2007;100(2):155–7.CrossRefPubMed

12.

Tsuneyoshi N, Fukudome K, Horiguchi S, et al. Expression and anticoagulant function of the endothelial cell protein C receptor (EPCR) in cancer cell lines. Thromb Haemost. 2001;85(2):356–61.PubMed

13.

Scheffer GL, Flens MJ, Hageman S, et al. Expression of the vascular endothelial cell protein C receptor in epithelial tumour cells. Eur J Cancer. 2002;38(11):1535–42.CrossRefPubMed

14.

Anton I, Molina E, Luis-Ravelo D, et al. Receptor of activated protein C promotes metastasis and correlates with clinical outcome in lung adenocarcinoma. Am J Respir Crit Care Med. 2012;186(1):96–105.CrossRefPubMed

15.

Heng W, Mu CY, Chen C, et al. Endothelial cell protein C receptor (EPCR) is expressed by lung carcinoma and correlated with clinical parameters. Clin Lab. 2013;59(3–4):375–80.PubMed

16.

Ducros E, Mirshahi S, Azzazene D, et al. Endothelial protein C receptor expressed by ovarian cancer cells as a possible biomarker of cancer onset. Int J Oncol. 2012;41(2):433–40.PubMedCentralPubMed

17.

Beaulieu LM, Church FC. Activated protein C promotes breast cancer cell migration through interactions with EPCR and PAR-1. Exp Cell Res. 2007;313(4):677–87.CrossRefPubMedCentralPubMed

18.

Bretschneider E, Uzonyi B, Weber AA, et al. Human vascular smooth muscle cells express functionally active endothelial cell protein C receptor. Circ Res. 2007;100(2):255–62.CrossRefPubMed

19.

Domotor E, Benzakour O, Griffin JH, et al. Activated protein C alters cytosolic calcium flux in human brain endothelium via binding to endothelial protein C receptor and activation of protease activated receptor-1. Blood. 2003;101(12):4797–801.CrossRefPubMed

20.

Gramling MW, Beaulieu LM, Church FC. Activated protein C enhances cell motility of endothelial cells and MDA-MB-231 breast cancer cells by intracellular signal transduction. Exp Cell Res. 2010;316(3):314–28.CrossRefPubMedCentralPubMed

21.

Schaffner F, Yokota N, Carneiro-Lobo T, et al. Endothelial protein C receptor function in murine and human breast cancer development. PLoS One. 2013;8(4):e61071.CrossRefPubMedCentralPubMed

22.

Keshava S, Kothari H, Rao LV, Pendurthi UR. Influence of endothelial cell protein C receptor on breast cancer development. J Thromb Haemost. 2013;11(11):2062–5.CrossRefPubMed

23.

Keshava S, Sahoo S, Tucker TA, Idell S, Rao LV, Pendurthi UR. Endothelial cell protein C receptor opposes mesothelioma growth driven by tissue factor. Cancer Res. 2013;73(13):3963–73.CrossRefPubMedCentralPubMed

24.

Van Sluis GL, Niers TM, Esmon CT, et al. Endogenous activated protein C limits cancer cell extravasation through sphingosine-1-phosphate receptor 1-mediated vascular endothelial barrier enhancement. Blood. 2009;114(9):1968–73.CrossRefPubMedCentralPubMed

25.

Bezuhly M, Cullen R, Esmon CT, et al. Role of activated protein C and its receptor in inhibition of tumor metastasis. Blood. 2009;113(14):3371–4.CrossRefPubMed

26.

Van Sluis GL, Brüggemann LW, Esmon CT, et al. Endogenous activated protein C is essential for immune-mediated cancer cell elimination from the circulation. Cancer Lett. 2011;306(1):106–10.CrossRefPubMedCentralPubMed

Titel: Endothelial cell protein C receptor promotes MGC803 gastric cancer cells proliferation and migration by activating ERK1/2
verfasst von: Qingling Wang
Qingru Liu
Tianyuan Wang
Hongli Yang
Zhengjie Han
Peng Zhang
Publikationsdatum: 01.05.2015
Verlag: Springer US
Erschienen in: Medical Oncology / Ausgabe 5/2015
Print ISSN: 1357-0560
Elektronische ISSN: 1559-131X
DOI: https://doi.org/10.1007/s12032-015-0614-y

Neu im Fachgebiet Onkologie

23.04.2024 | Medikamente in Schwangerschaft und Stillzeit | Nachrichten

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Endothelial cell protein C receptor promotes MGC803 gastric cancer cells proliferation and migration by activating ERK1/2

Abstract

Neu im Fachgebiet Onkologie

ICI-Therapie in der Schwangerschaft wird gut toleriert

Krebspatienten impfen: Was? Wen? Und wann nicht?

Müde im Alter? Auch an die Nebenniere denken

Stufenschema weist Prostatakarzinom zuverlässig nach

Update Onkologie

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 5/2015

Comment on “Prognostic performance of inflammation-based prognostic indices in patients with resectable colorectal liver metastases”

Chemoradiation therapy reduces aldehyde dehydrogenase 1 expression in cervical cancer but does not improve patient survival

Erratum to: Knockdown of HMGN5 suppresses the viability and invasion of human urothelial bladder cancer 5637 cells in vitro and in vivo

Hydroxyethyl starch 200/0.5 decreases circulating tumor cells of colorectal cancer patients and reduces metastatic potential of colon cancer cell line through inhibiting platelets activation

1H-MRS evaluation of breast lesions by using total choline signal-to-noise ratio as an indicator of malignancy: a meta-analysis

Erratum to: Prognostic factors for brain metastases from non-small cell lung cancer with EGFR mutation: influence of stable extracranial disease and erlotinib therapy

Neu im Fachgebiet Onkologie

ICI-Therapie in der Schwangerschaft wird gut toleriert

Krebspatienten impfen: Was? Wen? Und wann nicht?

Müde im Alter? Auch an die Nebenniere denken

Stufenschema weist Prostatakarzinom zuverlässig nach

Update Onkologie